Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

iTeos Therapeutics, Inc. (ITOS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
27.25+0.20 (+0.74%)
At close: 04:00PM EDT
25.89 -1.36 (-4.99%)
After hours: 04:11PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close27.05
Open26.71
Bid20.00 x 900
Ask29.50 x 1000
Day's Range26.34 - 27.41
52 Week Range16.21 - 52.43
Volume352,177
Avg. Volume488,232
Market Cap968.484M
Beta (5Y Monthly)1.50
PE Ratio (TTM)3.33
EPS (TTM)8.18
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
148% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for ITOS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iTeos Therapeutics, Inc.
    ITOS: Rating decreased to a HOLDITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference

    WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 02, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in a panel discussion at the upcoming 2022 Wedbush PacGrow Healthcare Conference titled: “IOs Wide Open – Opportunities and Challenges i

  • Investopedia

    Top Biotech Stocks for Q3 2022

    The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. Many biotech companies have shifted their focus entirely or added COVID-19 vaccines and treatments to their product pipeline. Early-stage biotech companies are prone to wild swings in revenue due to going from nearly no revenue to having a significant revenue stream once a drug is approved or a partnership with another company is reached.

  • Simply Wall St.

    iTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

    With its stock down 38% over the past three months, it is easy to disregard iTeos Therapeutics (NASDAQ:ITOS). But if...

Advertisement
Advertisement